{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-280116","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.593370+00:00","generated_at":"2026-05-16T20:20:21.572072+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CV Sciences Q3 revenue $3.3M (-16% YoY); adjusted EBITDA loss $118K; hemp regulatory language enacted with 1-yr delay","bullets":["Revenue $3.3M, down 16% YoY from $3.9M; net revenue from products launched since Jan 2023 contributed 39%.","Gross margin 48.5% (Q3 2024: 46.0%; Q2 2025: 50.9%); adjusted EBITDA loss $118K vs $75K loss in Q3 2024.","Cash balance $0.4M at quarter-end; launched +PlusCBD Ignite men's formula. Federal hemp language enacted with one-year delay."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-280116","json":"https://secwatch.observer/filing/0001193125-25-280116.json","markdown":"https://secwatch.observer/filing/0001193125-25-280116.md","text":"https://secwatch.observer/filing/0001193125-25-280116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000119312525280116/0001193125-25-280116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000119312525280116/cvsi-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:20:21.572072+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}